- Lexaria is a global innovator that has developed the patented DehydraTECH(TM) technology that improves bioavailability, speed of onset, and brain absorption of active pharmaceutical ingredients (“APIs”)
- The company strategically partners with third-party organizations seeking to explore formulation opportunities with their specific APIs
- Lexaria is evaluating the effectiveness of various DehydraTECH-processed APIs, including CBD, nicotine, sildenafil, and more
- According to company CEO Chris Bunka, the management team is positioning the company to ensure that it has multiple paths to success
In pursuit of multiple paths to success, Lexaria Bioscience (NASDAQ: LEXX), developer of the patented DehydraTECH(TM) drug delivery platform, strategically partners with third-party companies looking to explore formulation opportunities with their targeted APIs, out-licenses its technology, and is actively developing lead product candidates. According to a 2021 video, the company also hopes to provide a lifeline to pharmaceutical companies noting that DehydraTECH(TM) “may provide additional patent extensions for existing drugs, which is a potential billion-dollar insurance policy to original drug manufacturers” (https://cnw.fm/6OXrO).
So named because it features a dehydration synthesis procedure, the DehydraTECH technology has been found to improve bioavailability, speed of onset, and brain absorption of active pharmaceutical ingredients (“APIs”). To discover more about the effectiveness of DehydraTECH, Lexaria has studied the DehydraTECH processing of various APIs, most recently the phosphodiesterase inhibitor (“PDE5 inhibitor”) sildenafil – whose most widely known product available for sale is Viagra(R) – for potential application in the management of erectile dysfunction.
The animal study revealed that DehydraTECH resulted in faster and higher overall delivery of sildenafil into the bloodstream (https://cnw.fm/PSGMO) than concentration-matched controls. Valued at $4.99 billion in 2021, the erectile dysfunction drug market is expected to grow at a CAGR of about 4.6% between 2021 and 2025, reaching $5.97 billion (https://cnw.fm/44fYi).
Other DehydraTECH markets being evaluated by Lexaria include the broader cannabidiol (“CBD”) market, which is projected to grow at a 51% CAGR from a value of $2.7 billion in 2021 to approximately $111 billion by 2030 (https://cnw.fm/O3trM).
CBD is increasingly used in a myriad of applications that Lexaria is equally targeting. The company recently announced it had begun the first phase of its epilepsy animal research to evaluate the seizure-inhibiting activity of DehydraTECH-CBD compared to Epidiolex(R), the sole FDA-approved CBD-based seizure drug (https://cnw.fm/bfRQi). The global epilepsy market, valued at $10.3 billion in 2020 and 10.6 billion in 2021, is projected to grow to $12.9 billion in 2026 and $16.6 billion by 2031 (https://cnw.fm/qEOVQ).
In addition, Lexaria is evaluating DehydraTECH-CBD as a potential treatment for hypertension, announcing late last year it had received an Independent Review Board (“IRB”) approval ahead of schedule for its fourth DehydraTECH-CBD human hypertension study, HYPER-H21-4, tentatively set to begin this month (https://cnw.fm/FCtDb). HYPER-H21-4 will build on previous human and animal research, which demonstrated that DehydraTECH-processed CBD results in a rapid and sustained drop in blood pressure and reduces arterial stiffness.
The World Health Organization reports that an estimated 1.28 billion aged between 30 and 79 years have hypertension. But, of concern, only about 1 in 5 persons have it under control (https://cnw.fm/bYiFe). DehydraTECH-CBD could therefore provide patients the much-needed reprieve, enabling Lexaria to also tap into the global hypertension drugs market expected to grow at a CAGR of 3.4% from a value of $24.4 billion in 2020 to $31.5 billion by 2028 (https://cnw.fm/P7kRs).
Lexaria has also evidenced faster and more effective delivery of DehydraTECH-processed nicotine. Results from an animal study, the NIC-A21-1, announced last fall, showed that DehydraTECH-oral nicotine peaked in the bloodstream 10x to 20x faster than controls. At the same time, the peak levels achieved were up to 10x higher than controls. Valued at $59.8 billion in 2021, the global nicotine replacement therapy market is expected to reach $147.9 billion by 2028, growing at a 16.3% CAGR (https://cnw.fm/uNa61).
“We are currently pursuing or investigating several large market opportunities, the smallest of which is currently generating over $1 billion in annual revenue. In many of these markets, growth is expected to be significant over the next several years. The Lexaria management team is trying to ensure that we have multiple paths to success: if any one single area of investigation were to fail, we want to ensure we still have other opportunities to exploit,” wrote Lexaria CEO Chris Bunka in an annual letter to stakeholders (https://cnw.fm/7Cd6E).
For more information, visit the company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX
About CBDWire
CBDWire (CBDW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CBDNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CBDW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CBDW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CBDW brings its clients unparalleled visibility, recognition and brand awareness. CBDW is where news, content and information converge.
Receive Text Alerts from CBDWire: Text “Cannabis” to 21000
For more information please visit https://www.cbdwire.com and or https://CBDWire.News
Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer
CBDWire (CBDW)
Denver, Colorado
cbdwire.com
303.498.7722 Office
Editor@CBDWire.com
CBDWire is part of the InvestorBrandNetwork.